Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes

Inclusion Criteria: * Type 2 diabetes mellitus * Diet treated and/or subjects in monotherapy with max. 50 % of maximal dose of sulphonylurea (SU). In addition, subjects in treatment with metformin and/or repaglinide could be included * Body Mass Index (BMI) maximum 35 kg/m\^2 * Fasting plasma glucose 7-15 mmol/l, both inclusive Exclusion Criteria: * Impaired liver function * Impaired renal function * Anaemia * Cardiac disease * Uncontrolled treated/untreated hypertension * Recurrent major hypoglycaemia as judged by the Investigator * Known or suspected allergy to trial product or related products * Females of child bearing potential who are pregnant, breast-feeding or have intention of becoming pregnant or are not using adequate contraceptive measures * Current treatment with thiazolidinediones or chronic daily use of insulin (more than 7 days) within three months in the absence of intercurrent illness * Loss of more than 400 ml blood during the three months prior to study start * Allergy to paracetamol